domingo, 19 de abril de 2020

Biophysical characterization of the SARS-CoV2 spike protein binding with the ACE2 receptor explains increased COVID-19 pathogenesis R Chowdhury et al, BIORXIV, April 12, 2020

Hot Topics of the Day|PHGKB
Coronavirus
We describe early mutational events across samples from publicly available sequences. Of 30 high quality datasets, 27 datasets (90%) contain at least a single founder mutation and most of the variants are missense (over 63%). Five-point mutations with clonal (founder) effect were found in USA sequencing samples.
No proven effective therapies for this virus currently exist. The rapidly expanding knowledge regarding SARS-CoV-2 virology provides a significant number of potential drug targets. The most promising therapy is remdesivir. Remdesivir has potent in vitro activity against SARS-CoV-2, but it is currently is being tested in ongoing randomized trials.
No other method provides continuous, real-time monitoring of people besides digital technologies. To contemplate reopening our economy without putting public health at unnecessary risk, we need a practical strategy that exploits our digital infrastructure.

No hay comentarios:

Publicar un comentario